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Abstract In chronic kidney disease (CKD), once injury
from any number of disease processes reaches a
threshold, there follows an apparently irreversible course
toward decline in kidney function. The tubulointersti-
t i u mm a yp l a yak e yr o l ei nt h i sc o m m o np r o g r e s s i o n
pathway. Direct injury, high metabolic demands, or
stimuli from various other forms of renal dysfunction
activate tubular cells. These, in turn, interact with
interstitial tissue elements and inflammatory cells,
causing further pathologic changes in the renal paren-
chyma. The tissue response to these changes thus
generates a feed-forward loop of kidney injury and
progressive loss of function. This article reviews the
mechanisms of this negative cycle mediating CKD.
Keywords Fibrosis.Inflammation.Hypoxia.Proteinuria
Introduction
The tubulointerstitium includes the tubules, which comprise
about 80% of the kidney volume, and the compartment of
the kidney bounded by the vasculature and nephrons. This
component of the kidney performs critical functions
(Table 1), including the selective reabsorption and excretion
of filtered molecules and the production and release of
hormones. As such, the tubulointerstitium has a high energy
demand and is susceptible to injury in situations of relative
nutrient deprivation. It is involved in a multitude of disease
processes, including obstructive uropathy, reflux nephrop-
athy, pyelonephritis, metabolic disorders, hereditary dis-
eases, and toxin exposures. Given the importance of the
tubulointerstitium and its sensitivity to injury, it is not
surprising that many of its physiological functions, when
exaggerated, account for clinical manifestations of chronic
kidney disease (CKD).
The contribution of deranged tubulointerstitial function
to these manifestations raises a question as to the possible
involvement of this compartment in the pathophysiology of
progressive loss of kidney tissue as well. In CKD, once
kidney damage reaches a threshold, the subsequent pro-
gression appears to be largely irreversible and independent
of the initial kidney injury. It is theorized that the myriad
primary kidney injuries that lead to end-stage kidney
disease (ESKD) converge into one or more final common
pathway(s) of disease progression. Tubulointerstitial injury
and the cascade of events that it elicits may be one of these
pathways.
The purpose of this educational review is to consider the
mechanisms of progression that have been proposed to
involve the tubulointerstitium. We emphasize that a purely
negative physiological process is unlikely to exist, since
biology has evolved to preserve and improve function.
Therefore, in other circumstances the involved mechanisms
are beneficial. For example, macrophages may help repair
lesions by recruiting cellular elements and producing a
provisional extracellular matrix (ECM), but these same
actions may mediate inflammation or produce fibrogenic
cytokines. This concept of misdirected repair has been
considered in a previous issue of Pediatric Nephrology [1].
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Two models have been proposed for how kidney injury
leads to ESKD, with emphasis on the involvement of the
glomeruli and the tubulointerstitium, respectively [2]. In the
“overload hypothesis,” an initial kidney injury results in a
decrease in the number of functioning nephrons. In
response, the remaining nephrons manifest compensatory
increases in function. This causes further nephron damage
and loss, generating a feed-forward cycle that leads to
ESKD. Alternatively, the “fibrosis hypothesis” suggests
that a variety of initial kidney insults result in tubulointer-
stitial injury, eliciting further inflammation and damage to
the tubulointerstitium that proceeds to ESKD. These path-
ways are not mutually exclusive, but represent two ways of
conceptualizing the progressive nature of CKD.
The scientific literature has implicated the tubulointer-
stitium in progressive kidney loss for several decades. In
1970, Schainuck and colleagues defined a pathologic
correlate for declining glomerular filtration rate (GFR) in
patients with various glomerulopathies [3]. These research-
ers found that GFR was inversely related to the severity of
interstitial damage seen in biopsy samples. In contrast, a
relationship between GFR and histologic severity of
glomerular injury was not found. Further studies showed
that increased interstitial volume and fibrosis, a decrease in
peritubular capillaries, morphologic changes in tubular
epithelial cells, and intensity of interstitial inflammation
all correlate with kidney function deterioration [4].
This relationship between tubulointerstitial injury and
deteriorating kidney function could have been influ-
enced by both sampling bias and the pattern of
glomerular damage [5]. Glomerular histology may be
more subject to sample bias in diseases with focal
Table 1 Functions of the tubulointerstitium
Functions of the tubulointerstitium
Transport functions
Electrolyte balance
Volume homeostasis
Osmolarity
Acid–base balance
-chloride transport
-bicarbonate regeneration
-ammoniagenesis
Phosphate metabolism
Selective protein reabsorption
Metabolic function
Gluconeogenesis
Hormonal function
Vitamin D metabolism
Erythropoiesis
Blood pressure
-renin–angiotensin system
-endothelins
-prostaglandins, prostacyclin
Glomerular
Injury
Tubular
Injury
Genetic
Toxic
Metabolic
Ischemic
Infectious
Increased 
Metabolic 
Demands
Distal Tubular 
Cell Delivery
-Cytokines
-Lipids
-Complement
-ROS
-Iron
Tubular Cell Activation
Tubulointerstitial 
Transudation
-Cytokines
-Lipids
-Complement
-ROS
-Other plasma
components
Ischemia/Hypoxia
Proteinuria
Remnant
Hypertrophy
Synechia 
Formation
Podocyte Depletion Glomerular Loss
Nephron 
Overload
Fig. 1 Glomerular or tubular injury initiates chronic kidney disease
(CKD), but the tubulointerstitial response is primarily responsible for
progression. (1) Podocyte dysfunction or depletion leads to protein-
uria, causing reactive changes in the tubular cells. (2) Podocyte
depletion also permits the transudation of glomerular filtrate directly
into the periglomerular tubulointerstitium, depositing a number of
biologically active molecules in that compartment. (3) As the number
of effective nephrons decreases, the remaining nephrons hypertrophy.
An increased amount of filtrate per nephron increases metabolic
demand on the tubules, which under even normal circumstances have
high energy requirements. Thus, further stress on tubule cell
homeostasis results in activation of the cells, away from a state of
relatively orderly transporter function. ROS Reactive oxygen species
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general, glomerular pathology can be heterogeneous due
to the coexistence of hyperfunctioning, enlarged glomeruli
and scarred glomeruli in the same biopsy sample [6].
However, the possibility must be considered that tubu-
lointerstitial injury is the major causal event associated
with the progressive decline in kidney function in all
forms of CKD. To understand this concept further, it is
important to consider the mechanisms by which tubuloin-
terstitial injury occurs and to examine the pathologic
consequences of the response to that injury.
Changes in glomerular function can initiate
tubulointerstitial damage
Abnormal glomerular filtration can initiate progression to
CKD, inducing a tubulointerstitial response, as depicted in
Fig. 1. Here, we will examine the concepts of misdirected
filtration, obstruction of filtrate flow, and proteinuria.
Misdirected filtration Kriz and colleagues have proposed a
mechanism by which filtrate leakage external to the tubular
lumen damages the tubulointerstitium [2]. Chronic damage
to the glomerulus elicits a consistent pattern of changes
characterized by foot process effacement and, eventually,
podocyte loss. The resulting areas of denuded glomerular
basement membrane can adhere to parietal epithelial cells,
forming a bridge between the glomerular and parietal
basement membranes. An adhesion, or synechia, thus forms
between the affected portion of the glomerular tuft and
Bowman’s capsule. At this adhesion, the filtrate is extruded
directly into the periglomerular interstitium. In response to
plasma proteins, interstitial fibroblasts are recruited to and/
or proliferate at the site of the transudate. Inflammation and
fibrosis develop around the glomerulus, resulting in local
tubular atrophy and subsequent degeneration.
Obstructed flow of filtrate The local response described in
the previous paragraph and/or crescent formation resulting
from endocapillary inflammation leading to extracapillary
cellular proliferation may obstruct the glomerulotubular
junction and the initial segment of the proximal tubule,
blocking the outflow of filtrate from Bowman’s capsule [2].
The result is tubular atrophy and degeneration. In a murine
model of glomerulonephritis, [7] tubular degeneration was
seen only in those tubules associated with glomeruli that
had cellular crescents extending into the tubular lumen.
Glomeruli with crescent formation not involving the
glomerulotubular junction were associated with morpho-
logically normal initial proximal tubule segments.
Proteinuria Tubulointerstitial injury also can be caused by
increased delivery of physiologically active molecules to
the tubular lumen. Severity of protein excretion has been
consistently associated with a greater likelihood of decline
in GFR, and treatments aimed at ameliorating proteinuria
slow this decline. Studies of both animal models and
human kidney biopsy specimens have shown various
pathologic injuries to the tubulointerstitium related to
proteinuria, including tubular epithelial cell apoptosis and
epithelial-to-mesenchymal transition (EMT) [8]. Increased
reabsorption of biologically active molecules increases met-
abolic demand on the remaining nephrons. A caveat to these
observations isthat, insomecases,increased nephron damage
might cause proteinuria rather than the other way around.
Consistent with this view, unremitting proteinuria in cases of
treatment-resistant, true minimal change nephropathy has not
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Fig. 2 Activated tubular cells
participate in a number of pro-
cesses that lead to progressive
glomerular loss. While it is not
clear that the cells directly pro-
duce extracellular matrix to
yield a scar, they do produce
cytokines, support inflammatory
responses, and dedifferentiate or
die. The result is nephron loss
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although “severity” of proteinuria usually has been charac-
terized by the amount of protein present, it is likely that a
specific characteristic of the proteinuria—such as the nature
of the molecules that are present in the filtrate—is essential
for it to cause tubulointerstitial damage. Conversely, it is
worth noting that, if tubular reabsorptive mechanisms are
disturbed, increased urine protein could represent a result,
rather than a cause, of tubular damage in progressive CKD.
Activation of tubular cells: a central event
in progressive tubulointerstitial disease
Assuming that in many cases proteinuria does cause
tubulointerstitial injury, several mechanisms might be
implicated based on events observed in acute processes
[8, 9]. Protein casts may obstruct the tubular lumen.
Tubular cells may be damaged as protein reabsorption is
increased in response to filtered load, possibly through
overloading and rupture of lysosomes or by an overwhelm-
ing energy demand on the tubular cells. However, these
mechanisms have not been proven by experimental evi-
dence. Non-protein substances in the urine could be toxic to
the cells. Ultimately, the biologically active molecules
present in the proteinuric filtrate induce changes in tubular
cells from being highly differentiated to a less differentiated
state wherein they mediate a variety of pathogenic
processes. Thus, instead of serving as a polarized barrier
that regulates the transport of molecules into and out of the
glomerular filtrate, the activated epithelium releases cyto-
kines, recruits inflammatory cells and fibroblasts, and
serves as a source of stimuli of other cellular events that
contribute to CKD (Fig. 2).
Response to filtered load of plasma molecules The roles of
different filtered molecules in the pathogenesis of progres-
sion are uncertain. In the normal state, the three proteins
megalin, cubilin, and amnionless form a receptor complex
that efficiently binds and reabsorbs filtered albumin and
other proteins in the proximal tubule [10]. Megalin is a
large transmembrane protein and a member of the low-
density lipoprotein receptor family; its intracellular tail
includes phosphorylation, signaling, and protein interaction
motifs that may enable it to initiate intracellular signaling
cascades [11]. Cubilin colocalizes with megalin on the
proximal tubule membrane and is required for albumin
binding, whereas megalin is important for internalization of
a l b u m i ni n t ot h ec e l l[ 12]. Amnionless facilitates the
transport of cubilin to the proximal tubule membrane and
assists in ligand endocytosis [10]. When tubular protein
delivery increases, such as in glomerular damage, the
capacity of the receptor complex is likely overwhelmed,
resulting in the increased delivery of proteins and other
toxins to the more distal tubule [10].
Albumin stimulates tubular cell nuclear factor kappa-B
(NF-κB) and signal transducer and activator of transcription
(STAT), which in turn upregulate chemokines, including
macrophage chemotactic factor 1 (MCP-1) and regulated
upon activation, normal T cell expressed, and secreted
(RANTES),andleadtoinflammatoryinfiltrationandeventual
tubular injury [5]. Blocking the action of MCP-1 or chemo-
kine receptor-1 (CCR-1) in animal models of progressive
renal injury results in the reduction of tubulointerstitial
inflammation and fibrosis [13, 14]. Other mediators that
could play a role in disease progression, not necessarily
directly attributable to albumin stimulation, include plasmin-
ogen activators, matrix metalloproteinases, and their inhib-
itors [15]. Increased formation of reactive oxygen species
(ROS) as a response to albuminuria may further add to
tubulointerstitial damage. Reabsorption of albumin in the
proximal tubule cell leads to concomitant activation of
NADPH oxidase and ROS generation through the activation
of Rac1, a GTPase involved in albumin endocytosis [16].
In considering the pathogenesis of tubulointerstitial
injury, it is important to bear in mind that albumin is a
major intravascular carrier protein, and that some effects
attributed to albumin actually may represent the effect of
other albumin-bound molecules. For example, iron has
been proposed to be a tubular toxin/activator [17]b y
generating ROS. Additional molecules, bound to albumin
or not, may contribute to mechanisms of progression.
Several examples are offered here.
Lipids Lipids or their breakdown products may cause tubular
injury and atrophy. In animal models, exposure to albumin-
boundfreefattyacidsresultedinmoreseveretubulointerstitial
damage than exposure to albumin alone, as well as in
increased macrophage infiltration and increased expression
of markers of epithelial damage and fibrosis [18, 19]. Fatty
acids activate peroxisome proliferator-activated receptors
(PPAR) in human proximal tubule cells, resulting in cell
apoptosis [20]. They also may mediate lipid peroxidation
reactions. Oleic acid-bound albumin administration [21]
induces ROS production in vitro through a proline-rich
tyrosine kinase 2 (Pyk2)-dependent pathway. An acidic
environment, as is often present in the tubular lumen in
kidney disease, enhances ROS production after exposure to
oleic acid-bound albumin.
Complement Protein overload in the proximal tubule is also
associated with complement activation and deposition and
with subsequent tubulointerstitial damage [8]. Inhibition of
the membrane attack complex, or C5b-9, results in decreased
progression of tubulointerstitial damage and less impairment
of creatinine clearance in proteinuric rats [22, 23].
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The activation of the tubular cell represents a dedifferenti-
ation from a highly specialized, polarized transport epithe-
lium to one with a variety of synthetic and other activities.
It has been proposed by some investigators that this
dedifferentiation represents a return to a primordial pheno-
type, since the tubular cells were derived during organo-
genesis from mesenchymal cells condensing around the
ureteric bud in a mesenchymal-to-epithelial transition. An
important series of questions involves the role of these
dedifferentiated tubular cells in progression and the specific
origin of the cells that produce excessive ECM [24]. These
will be considered further in the next section. Regarding the
fate of the dedifferentiated tubular cells, it is likely that such
cells manifest a variety of phenotypes that contribute to
progression. It has been difficult to detect a transitional
form between the tubular epithelial cell and a myofibroblast
that produces ECM. However, the dedifferentiated tubular
epithelial cell may not involve the synthesis of scar tissue.
Increased synthetic activity by these cells creates further
metabolic demand. The secreted molecules pathologically
activate other cells in the tubulointerstitium. The result is
nephron loss, increased filtration of biologically active
molecules through overloaded, remnant nephrons, and a
cycle of intensification of all the mechanisms of progres-
sion that have been activated.
The origin of the fibrogenic cell These changes in the
tubulointerstitium alter the existing balance between ECM
degradation and synthesis. Disruption of this balance
affects mechanisms that are activated to heal injuries,
resulting in misdirected repair that leads to scar formation
[1]. As alluded to in the previous section, a critical
question, yet to be resolved, is the origin of the myofibro-
blast that is actually producing the ECM that becomes scar
tissue. While some investigators have suggested that this
myofibroblast represents a dedifferentiated tubular cell,
referred to as EMT, others have implicated circulating cells,
perhaps those derived from the bone marrow as either
Juxtaglomerular 
Cells
Renin production
Pericyte
Differentiation into
 fibroblast?
Macrophages
Inflammatory mediators
Proteases
Procoagulants
Myofibroblasts
Extracellular matrix
Endothelial 
Cells
Apoptosis
Procoagulants
Endo-MT
Tubular cells
Antigen presentation
Apoptosis
Profibrotic cytokines
Fig. 3 Different cell types con-
tribute to progressive nephron
loss. Juxtaglomerular cells pro-
duce renin, affecting tubuloglo-
merular feedback to alter
glomerular filtration and acti-
vating extracellular matrix
(ECM) production by multiple
cell types. Tubular cells dedif-
ferentiate to recruit inflammato-
ry cells and activated fibroblasts.
These myofibroblasts may be
derived from vascular pericytes,
circulating or resident fibro-
blasts, or endothelial cells.
Macrophages also promote in-
flammation and tissue damage
through protease production.
Endothelial cell apoptosis accel-
erates hypoxic and ischemic
changes of the tubular and in-
terstitial cells. The production of
soluble mediators by these cells
permits them to interact in a way
that under ideal circumstances
orchestrates a healing response,
but in CKD promotes a vicious
cycle of misdirected repair
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with tissue stem-cell potential, such as the vascular pericyte
(Fig. 3)[ 25]. Recent evidence also has suggested a potential
role for the transition of endothelial cells to a more
mesenchymal phenotype (EndoMT), either causing the loss
of peritubular vessels [26] or directly leading to myofibro-
blasts [27]. It is important to again emphasize that these
changes may not be required solely for the generation of
scar-producing cells. Alterations in the endothelial or tubular
cell phenotype could contribute to the activation of myofi-
broblasts, or to the recruitment and/or activation of other
cells that contribute to progressive disease.
Changes consistent with EMT in the tubulointerstitium
have been demonstrated in studies of animal models and
human biopsy samples [28]. A primary mediator of this
response in the kidney is transforming growth factor-beta
(TGF-β), a ubiquitous cytokine that effects changes in gene
expression that impact cell growth, differentiation, apopto-
sis, and ECM deposition. In response to nephron injury of
various etiologies, TGF-β expression is upregulated and
induces EMT in renal tubule cells [29]. Other potential
contributors include connective tissue growth factor
(CTGF) [30], which can, like TGF-β, stimulate cellular
production of ECM, and plasminogen activator inhibitor
(PAI)-1, which can impair the degradation of accumulated
ECM [31]. Importantly, these growth factors may be
contributed by different types of cell or tissue, so that
communication among the tubular and interstitial cells
plays a significant part in the pathogenesis of progression.
Inflammation The dedifferentiated tubular cell produces
biologically active molecules, such as those listed above.
Cytokines, chemokines, biologically active lipids, and other
molecules stimulate the production of more mediators,
recruiting inflammatory cells to the tubulointerstitium.
Macrophages accumulate and release toxic enzymes, per-
oxides, cytokines, and pro-coagulants [32]. These may
propagate further injury; for example, in murine cell
cultures, activated macrophages induce proximal tubule
cell apoptosis [33]. In transplant rejection and tubulointer-
stitial nephritis, the injured tubular epithelial cell can
express molecules that mediate antigen presentation, there-
by provoking a cycle of inflammatory mediator production,
recruitment of inflammatory cells, and further inflamma-
tion. Although there are no data on specific antigen
presentation in the inflammation of CKD, such an action
could potentially play a role here as well.
Hypoxia Oxygen delivery to the tubulointerstitium relies on
diffusion between parallel arterial and venous vessels. This
countercurrent multiplier system results in a reduced
oxygen tension in the renal medulla of about 10 mm Hg;
Changes in GFR/Initiation 
of Tubulointerstitial 
Damage
￿Misdirected filtration
￿Obstructed tubular flow
￿Proteinuria
Tubular Cell Activation
￿Possible mediators include 
albumin or albumin-bound 
moieties, lipids, complement, 
reactive oxygen species
Propagation of Damage 
and Progression of CKD
￿Apoptosis
￿Hypoxia
￿ECM accumulation
Tubular Response to 
Tubulointerstitial Damage
￿Fibrogenesis
￿EMT
￿Inflammation
￿RAS activation
￿Apoptosis
Fig. 4 The cycle of dysfunction
in progressive CKD. Decreased
glomerular filtration rate (GFR)
or primary tubulointerstitial
damage leads to poorly func-
tioning glomeruli and the dele-
terious activation of tubular
cells. These cells communicate
with other cells to orchestrate a
series of events that trigger
mechanisms of interstitial in-
flammation, fibrosis, and cell
death. The result is loss of
peritubular capillaries, tubular
cell apoptosis and necrosis, and
nephron loss. Hypertrophic
responses to these events further
damage the remnant glomeruli
and tubules, propagating the
cycle of injury and misdirected
repair. RAS Renin–angiotensin–
aldosterone system, EMT
epithelial-to-mesenchymal
transition
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an average partial pressure of oxygen of approximately
30 mmHg [34]. This comparatively low oxygen delivery
makes the kidney sensitive to changes in systemic
oxygenation. In disease processes that result in hypoxia,
therefore, renal tissue is prone to injury.
Recent evidence has indicated that patients who have
experienced acute kidney injury (AKI) have an increased
likelihood of progression to CKD, and patients with mild
CKD exhibit a markedly increased incidence of progression
to ESKD if they have an episode of AKI. Further, their rate
of progression is more rapid [35].
There are several potential explanations for this phe-
nomenon. The circulation to peritubular capillaries is
derived from the glomerular capillary effluent. Damage to
the glomerular capillary bed thus directly impairs peritub-
ular perfusion and oxygen supply and elicits microvascular
dysfunction [36]. Ischemia–reperfusion injury to the kidney
stimulates the dedifferentiation of endothelial cells [26].
Significant tubulointerstitial injury has been associated with
renal arteriolar and arterial damage and peritubular capillary
loss as well as with impaired oxygen diffusion [34]. Blood
flow delivered to the nephron may be inadequate for the
relatively increased metabolic demand of remaining hyper-
functioning nephrons in CKD. Finally, anemia occurs in
CKD due to several causes, including a deficiency of
erythropoietin production, and negatively affects the body’s
oxygen-carrying capacity.
Hypoxia itself induces the expression of a number of
genes that could contribute to the activation of tubulointer-
stitial processes leading to CKD. Vascular endothelial cell
growth factor (VEGF) and basic fibroblast growth factor
(FGF-2) influence the permeability of endothelial and
epithelial monolayers, activate cells to migrate and prolif-
erate, and may directly affect fibrogenesis [37]. The
activation of these genes is mediated by hypoxia-inducible
factor (HIF)-1α, which recently has been implicated in
several models of progressive glomerular and tubulointer-
stitial disease [38, 39]. Through the action of HIF-1α,
hypoxia activates fibroblasts and induces EMT, altering
ECM metabolism to promote scar accumulation [38]. HIF-
1α contributes to TGF-β-stimulated collagen expression
even under normoxic conditions [40]. Together, these data
strongly support the notion that hypoxia, whether related to
AKI or to the changes that occur in CKD, is an important
contributor to the progression of CKD.
Renin–angiotensin–aldosterone system Activation of the
renin–angiotensin–aldosterone system (RAAS) in kidney
injury elicits tubulointerstitial damage through a variety of
mechanisms both related to and beyond hemodynamic
changes. RAAS activation exacerbates hypoxia in the
tubulointerstitium by constricting the glomerular efferent
arterioles, leading to decreased downstream perfusion of the
peritubularcapillaries [34]. Angiotensin II upregulation alone
is associated with endothelial cell damage and increased
oxidative stress [34]. Angiotensin II induces FGF, platelet-
derived growth factor (PDGF), TGF-β, and PAI-1, all of
which may contribute to fibrosis [41]. In addition, aldoste-
rone production leads to the induction of ROS and the
production of inflammatory cytokines [42]. In kidney tubule
cell cultures, aldosterone administration was observed to
cause ROS production and oxidative DNA damage [43].
Beyond its effects on sodium reabsorption, aldosterone has
been linked more directly to fibrogenesis [44].
Physiological maintenance of the progression cycle
Abnormal glomerular filtration, inflammation, fibrogenesis,
and hypoxia, all common pathophysiological consequences
of various kidney diseases, contribute to tubulointerstitial
injury and activation as described thus far. In turn,
tubulointerstitial injury perpetuates a pathway of further
kidney injury, likely contributing to the progression of
CKD (Fig. 4).
Tubulointerstitial injury causes the accumulation of
inflammatory cells in the interstitium. Cytokines such as
TGF-β inhibit afferent arteriolar vasoconstriction. Extracel-
lular matrix proteins are altered, and there is a decrease in
the response of vascular smooth muscle cells to contractile
stimuli. Conversely, the activation of hypertensive mecha-
nisms stimulates vasoconstriction and decreased perfusion
of the tubulointerstitium [45]. In addition, tubulointerstitial
injury itself increases hypoxia and furthers kidney damage.
The increased inflammatory cell proliferation and down-
stream fibrosis that occur in the interstitium increases the
distance between tubules and the capillaries that supply
oxygen [5]. Moreover, the diffusion of oxygen through the
interstitium is limited by inflammation. Tubulointerstitial
fibrosis also has been correlated with a loss of peritubular
capillaries [5, 34]. A perpetuating pattern of kidney injury
is established, whereby hypoxia leads to tubulointerstitial
injury and inflammation, which in turn worsens renal
hypoxia.
Finally, tubular damage leads to tubular dropout and
resultant atubular glomeruli, decreasing the number of
functional nephrons. There is a compensatory increase in
remnant single-nephron blood flow in response. The
remaining nephrons hypertrophy, adapt to increased filtra-
tion pressure, and become more vulnerable to disease and
pathologic changes. Tubular atrophy also increases fluid
delivery to the macula densa and triggers a reduction in
GFR via tubuloglomerular feedback. Subsequently, there is
exacerbation of glomerulosclerosis, leading to further
Pediatr Nephrol (2012) 27:901–909 907filtrate leak and proteinuria, again perpetuating tubulointer-
stitial damage. Eventually, the capacity of the system to
respond by autoregulating glomerular blood flow is lost,
exacerbating hypoxia/ischemia and decreasing the number
of remaining functional nephrons.
Together, these events create a cycle of injury, cell
activation, and misdirected repair that is common to a wide
variety of causes of CKD. Further study of these biological
responses will enable us to better elucidate the mechanisms
of tubulointerstitial damage and determine possible path-
ways for therapeutic intervention.
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Questions (Answers provided following the reference list)
1. Histologic changes shown to correspond to worsening
GFR in CKD include all of the following EXCEPT:
A. Decreased number of peritubular capillaries
B. Severity of glomerular injury
C. Intensity of interstitial inflammation
D. Increased interstitial volume and fibrosis
2. Proteinuria and the presence of other molecules in the
filtrate affect tubulointerstitial cells by which of the
following mechanisms:
A. Proteinuria inhibits activity of the membrane attack
complex, or C5b-9
B. Albumin, acting through its receptor, megalin,
down-regulates NF-κB
C. Free fatty acids activate PPAR leading to tubular
cell apoptosis
D. Generation of ROS is decreased by exposure to
iron in the filtrate
3. Cells hypothesized to be the source of myofibroblasts
responsible for unbalanced production of ECM include
all of the following EXCEPT:
A. Tubular epithelial cells
B. Podocytes
C. Bone marrow precursor cells
D. Vascular pericytes
4. Tissue responses to tubulointerstitial injury include
which of the following:
A. Renal parenchymal blood flow is increased to
maintain unchanged oxygen tension
B. Inflammatory cells recruited to the tubulointer-
stitial milieu are inactivated by high urea
concentrations
C. Renin is inactivated, resulting in hypoxia and
oxidative stress
D. EMT is induced in part by the actions of TGF-β,
CTGF, and PAI-1
5. Tubular injury affects progression of chronic kidney
disease by which of the following pathways:
A. Hypoxia is worsened by capillary injury and
limitation of oxygen diffusion
B. Tubular dropout causes a decrease in single-
nephron blood flow of remaining glomeruli
C. Autoregulation of glomerular blood flow is
preserved
D. Atrophy of tubules results in increased filtrate
delivery to the macula densa, increasing GFR
through tubuloglomerular feedback
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